Tech Company Financing Transactions
Beeline Medicines Funding Round
On 6/30/2026, Beeline Medicines secured $126.3 million in Series A funding from Bain Capital Ventures, Bristol Myers Squibb and Canada Pension Plan Investment Board.
Transaction Overview
Company Name
Announced On
6/30/2026
Transaction Type
Venture Equity
Amount
$126,300,000
Round
Series A
Proceeds Purpose
The proceeds from the upsized Series A will support the initiation of several clinical studies across the Company's broad immunology portfolio, including planned pivotal development of its lead program, afimetoran, in lupus.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Clarendon Street
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Undisclosed
Website
Email Address
Overview
Beeline Medicines' executive team brings a proven track record building organizations that advance groundbreaking medicines from design to impact. Drawing on decades of leadership across drug discovery, clinical development, regulatory affairs, product commercialization, and business operations, we are driven by purpose, charting the most direct path to a new destination: a world where people with immune-mediated diseases can live life fully.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Saqib Islam
Chief Medical Officer
Nathalie Franchimont
Chief Technical Officer
Kristin Patterson
President
Badreddin Edris
VP - Human Resources
Daniel Pichl
Browse more venture capital transactions:
Prev: 6/30/2026: Build Technologies venture capital transaction
Next: 6/30/2026: Arcturus Technologies venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs